热线电话: 021-34661275
产品分类/PRODUCT CLASSIFICATION

上海细胞库

人源细胞系| 稳转细胞系| 基因敲除株| 基因点突变细胞株| 基因过表达细胞株| 重组细胞系| 猪的细胞系| 马细胞系| 兔的细胞系| 犬的细胞系| 山羊的细胞系| 鱼的细胞系| 猴的细胞系| 仓鼠的细胞系| 狗的细胞系| 牛的细胞| 大鼠细胞系| 小鼠细胞系| 其他细胞系|

原代细胞

原代细胞| 永生化细胞|

细胞培养

血清| 无血清冻存| 细胞培养试剂盒| 普通培养基| 完全培养基| 细胞污染预防| 细胞污染清除| 细胞培养辅助试剂|

细胞服务

STR鉴定服务| ATCC代购服务|

酶联试剂盒

人ELISA试剂盒| 大鼠ELISA试剂盒| 小鼠ELISA试剂盒| 兔ELISA试剂盒| 猪ELISA试剂盒| 鱼ELISA试剂盒| 牛ELISA试剂盒| 犬ELISA试剂盒| 鸭ELISA试剂盒| 豚鼠ELISA试剂盒| 鸡ELISA试剂盒| 绵羊ELISA试剂盒| 山羊ELISA试剂盒| 仓鼠ELISA试剂盒| 植物ELISA试剂盒| 药残留类试剂盒| 其他ELISA试剂盒|

生化试剂盒

生化试剂盒| 微量法检测盒| 分光法检测盒| 胶体金检测盒|

PCR试剂盒

荧光探针PCR试剂盒| 染料荧光PCR试剂盒| 核酸扩增/纯化| 普通PCR检测试剂盒| 质粒菌种感受态|

抗体蛋白

蛋白多肽| 抗体| 免疫组化| 免疫球蛋白|

试剂耗材

标准试液| 科研试剂| 缓 冲 液| 实验耗材| 高效液相色谱对照品|

首页 > 抗体蛋白 > 抗体
Brilliant Violet 421™ anti-mouse I-A/I-E Ant
产品名称：
Brilliant Violet 421™ anti-mouse I-A/I-E Ant
产品类别：
抗体
产品编号：
107631
产品应用：
107631
[价格]
规格 价格 库存
125µL ￥ 2112 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Activated C57BL/6 mouse spleen cells
Formulation
?l size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
?g size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421? under optimal conditions.
Concentration
?g size: 0.2 mg/mL
?L size: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
IHC-F - Verified

SB - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the ?l size, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood. For flow cytometric staining using the ?g size, the suggested use of this reagent is ≤ 0.25 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421? excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421? is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet?.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

The M5/114.15.2 antibody reacts with a polymorphic determinant shared by the I-Ab, I-Ad, I-Aq, I-Ed, and I-Ek MHC class II alloantigens from mice carrying H-2p,r,q,b,d,u haplotypes. Clone M5/114.15.2 however does not react wtih I-Af, I-Ak, or I-As MHC class II alloantigens.1

Additional reported applications (for the relevant formats) include: immunoprecipitation1, immunohistochemistry of frozen sections2,3,6, in vitro and in vivo blocking of antigen presentation or ligand binding4-7, and spatial biology (IBEX)17,18. The Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. Nos. 107655 & 107656).

Additional Product Notes

Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

Application References

(PubMed link indicates BioLegend citation)
  1. Bhattacharya A, et al. 1981. J. Immunol. 127:2488. (IP)
  2. Viville S, et al. 1993. Cell 72:635. (IHC)
  3. Nelson AJ, et al. 1993. J. Immunol. 151:2453. (IHC)
  4. Shi Y, et al. 1998. J. Exp. Med. 187:367. (Block)
  5. Yamashita I, et al. 1993. Int. Immunol. 5:1139.
  6. Guo M, et al. 1995. Zygote 3:65. (IHC)
  7. Kim A, et al. 2004. Exp. Mol. Med. 36:428. (Block)
  8. Luckashenak NA, et al. 2006. J. Immunol. 177:5177.
  9. Venanzi ES, et al. 2007. J. Immunol. 179:5693.
  10. Christensen SR, et al. 2006. Immunity 25:417. PubMed
  11. Matte-Martone C, et al. 2008. Blood 111:3884. PubMed
  12. De Pascalis R, et al. 2008. Infect. Immun. 76:4311. PubMed
  13. Kuns RD, et al. 2009. Blood 113:5999. PubMed
  14. Sabatino JJ, et al. 2011. J. Exp. Med. 208:81. PubMed
  15. Draber P, et al. 2011. Mol Cell Biol. 22:4550. PubMed
  16. Fu H, et al. 2014. Nat Commun. 5:3436. PubMed
  17. Radtke?AJ,?et al.?2020.?Proc Natl Acad Sci U S A.?117:33455-65. (SB)?PubMed
  18. Radtke?AJ,?et al.?2022.?Nat Protoc.?17:378-401. (SB)?PubMed
Product Citations
  1. Zhao Z, et al. 2021. Nat Commun. 12:4355. PubMed
  2. Hutton C, et al. 2021. Cancer Cell. 39:1227. PubMed
  3. Friess MC, et al. 2022. Cell Rep. 38:110334. PubMed
  4. Sagnella SM, et al. 2020. Cancer Cell. 37(3):354-370. PubMed
  5. Song Q, et al. 2022. Front Immunol. 13:920232. PubMed
  6. Iwamoto H et al. 2018. Cell metabolism. 28(1):104-117 . PubMed
  7. Sepe JJ, et al. 2022. JACC Basic Transl Sci. 7:915. PubMed
  8. Postat J et al. 2018. Immunity. 49(4):654-665 . PubMed
  9. Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed
  10. Potluri HK, et al. 2022. J Immunother Cancer. 10:. PubMed
  11. Ostendorf BN, et al. 2020. Nat Med. 26:1048. PubMed
  12. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  13. Mariani SA, et al. 2019. Immunity. 50:1439. PubMed
  14. Voisin M, et al. 2021. Commun Biol. 4:420. PubMed
  15. Wang F, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:257. PubMed
  16. Salei N, et al. 2020. J Am Soc Nephrol. 31:257. PubMed
  17. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  18. Reed J, et al. 2020. Bio Protoc. 10:e3607. PubMed
  19. Ferreira R, et al. 2016. J Infect Dis. 213: 669 - 673. PubMed
  20. Roberts LM, et al. 2021. iScience. 24:103025. PubMed
  21. Li Y, et al. 2021. Sci Transl Med. 13:. PubMed
  22. Panea C, et al. 2021. Commun Biol. 4:913. PubMed
  23. Tavazoie MF, et al. 2018. Cell. 172:825. PubMed
  24. Wang Y, et al. 2020. Cell Death Dis. 1.169444444. PubMed
  25. Lim CX, et al. 2020. Cell Rep. 3793:30. PubMed
  26. Grauel AL, et al. 2020. Nat Commun. 4.84375. PubMed
  27. Luo J et al. 2018. Immunity. 49(1):107-119 . PubMed
  28. Zhang Q, et al. 2021. Front Cell Dev Biol. 9:655552. PubMed
  29. Nair S, et al. 2021. JCI Insight. 6:. PubMed
  30. Taylor D, et al. 2022. Front Immunol. 13:936129. PubMed
  31. Wang YT, et al. 2020. Nat Microbiol. 0.397222222. PubMed
  32. Alam Z, et al. 2020. Cell Rep. 107825:31. PubMed
  33. Matsuda T, et al. 2022. iScience. 25:105324. PubMed
  34. Dong X, et al. 2022. Front Immunol. 13:896472. PubMed
  35. Takahashi F, et al. 2022. iScience. 25:104278. PubMed
  36. Nabet BY et al. 2017. Cell. 170(2):352-366 . PubMed
  37. Benci JL et al. 2019. Cell. 178(4):933-948 . PubMed
  38. Nenasheva T, et al. 2017. PLoS One. 12(6):e0178983. PubMed
  39. Zhang Q, et al. 2022. Commun Biol. 5:544. PubMed
  40. Dotsey E, et al. 2017. Sci Rep. 7:42584. PubMed
  41. Barbet G, et al. 2018. Immunity. 48:584. PubMed
  42. Lai SM et al. 2018. Cell reports. 25(11):3099-3109 . PubMed
  43. Xiao Y, et al. 2021. Cell. 184:6037. PubMed
  44. Kiss M, et al. 2020. Cancer Immunol Res. 9:309. PubMed
  45. Yu H, et al. 2021. Cell Death Dis. 13:1. PubMed
  46. Pantelidou C, et al. 2022. NPJ Breast Cancer. 8:102. PubMed
  47. Xu L, et al. 2022. Nat Commun. 13:6881. PubMed
  48. Sheng J, et al. 2021. eLife. 10:00. PubMed
  49. Kunishita Y, et al. 2020. Front Immunol. 11:98. PubMed
  50. Gu AQ, et al. 2019. J Cell Mol Med. 23(8):5403. PubMed
  51. Liang Z, et al. 2017. Autophagy. 14:505. PubMed
  52. Hirota K et al. 2018. Immunity. 48(6):1220-1232 . PubMed
  53. Mincham KT, et al. 2021. Front Immunol. 11:601494. PubMed
  54. Luo ZW, et al. 2021. Int J Nanomedicine. 16:2949. PubMed
  55. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  56. Mellal K, et al. 2019. Sci Rep. 9:12903. PubMed
  57. Liang Z, et al. 2022. iScience. 25:105233. PubMed
  58. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  59. Goddery EN, et al. 2021. Front Immunol. 12:726421. PubMed
  60. Sadiq BA, et al. 2020. Current Protocols in Immunology. 131(1):e115. PubMed
  61. Trivedi S, et al. 2020. Elife. 9:00. PubMed
RRID
AB_10900075 (BioLegend Cat. No. 107631) AB_2650896 (BioLegend Cat. No. 107632)

Antigen Details

Structure
MHC class II
Distribution

B cell and activated T cells, APCs of the H-2b,d,q,r bearing mice

Function
Antigen presentation
Ligand/Receptor
CD3/TCR, CD4
Cell Type
Antigen-presenting cells, B cells, Dendritic cells, T cells, Tregs
Biology Area
Immunology, Innate Immunity
Molecular Family
MHC Antigens
Antigen References

1. Watts C. 1997. Ann. Rev. Immunol. 15:821.
2. Pamer E, et al. 1998. Ann. Rev. Immunol. 16:323.

Gene ID
14961 View all products for this Gene ID 14969 View all products for this Gene ID
UniProt
View information about I-A/I-E on UniProt.org

联系我们

TEL：021-34661275 　点击拨打热线